Brazil In Vitro Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Brazil is adopting molecular DNA-HPV testing as the main cervical cancer screening tool, presenting a unique business opportunity for molecular IVD platforms. National guidelines were issued by the Ministry of Health in July 2025 for organised screening based on molecular testing for oncogenic HPV DNA. The guideline applies to women aged 25-64 years and allows a negative HPV test as the basis for five-year screening intervals. Nonetheless, implementation is crucial since INCA analysis in 2026 revealed that cervical screening rate among women aged 25-64 years in Brazil was only 39.03%. The transition therefore combines a technological shift toward PCR/molecular diagnostics with substantial scope for expanding testing access, laboratory capacity and sample-processing infrastructure across Brazil.

Brazil is increasing the utilization of genomic and genetic IVDs, shifting them from the specialized private testing into the context of precision medicine. The Genomas Brasil program by the Ministry of Health was designed to develop the necessary bases for the development of precision medicine, as well as its future implementation in SUS, through the combination of clinical and laboratory data, as well as the genome of the patient. In 2026, Brazil's CONITEC analyzed next-generation sequencing (NGS) approaches, which include genetic testing of BRCA1, BRCA2 and TP53 genes in people with personal and family history of breast cancer. Consequently, oncology is becoming an important application area for NGS, hereditary-risk testing and molecular profiling within the Brazilian IVD ecosystem.

Brazil's exceptionally high arbovirus burden is sustaining demand for rapid and laboratory-based diagnostic testing, particularly for dengue and other mosquito-borne infections. The Ministry of Health reported approximately 6.5 million probable dengue cases between epidemiological weeks 1 and 34 of 2024, demonstrating the scale of testing requirements during major outbreaks. The situation has subsequently fluctuated by epidemiological week 24 of 2026, Brazil had reported 392,816 probable dengue cases, representing a 73% reduction compared with the corresponding period of 2025. Such fluctuations increase the importance of flexible IVD capacity that can support outbreak surveillance, differential diagnosis and rapid confirmation. Molecular assays, antigen tests and other decentralised formats therefore remain important components of Brazil's infectious-disease diagnostic infrastructure.

The Brazilian oncology sector is creating a specialised market for next-generation sequencing and multi-gene molecular testing. As per the analysis conducted by CONITEC in 2026 on NGS, there will be genetic testing approaches that would include the use of BRCA1, BRCA2 and TP53 in addition to genetic counseling before and after testing for the patients with breast-cancer risk. This has been done because of the gravity of the underlying condition and the burden associated with it as Brazil was expected to have 704,000 new cancer cases between 2023-2025, excluding non-melanoma skin cancer, according to INCA estimates. NGS can simultaneously examine multiple genes, making it useful where hereditary cancer risk cannot be adequately assessed through a single-gene assay. Consequently, Brazilian IVD development is increasingly moving toward higher-complexity molecular workflows supporting risk assessment, tumour characterisation and treatment-related decision-making.

Brazil is increasingly integrating diagnostic results into digital disease-screening and patient-management platforms, rather than treating laboratory testing as an isolated step. A notable example is Pernambuco's organised cervical-cancer screening programme, where the Jordana platform integrates high-risk HPV test results from the laboratory environment with information on cytology, histopathology, colposcopy and treatment. The system allows intervals between screening, diagnosis and treatment to be monitored. This is particularly relevant because national cervical-screening coverage among women aged 25–64 was 39.03%, according to a 2026 INCA analysis. The trend therefore extends beyond laboratory automation. IVD systems are increasingly being connected with electronic records, screening databases and clinical decision pathways to improve follow-up after a diagnostic result.